Quantum BioPharma Ltd. (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments
- In the United States alone, close to one million people are living with MS, with a landmark study finding that figure was more than double what had previously been assumed.
- Treatments for progressive forms of MS remain especially elusive, and recent research notes that no currently approved therapy directly reverses the neurodegeneration that drives long-term disability.
- Quantum BioPharma’s Lucid-MS candidate is designed to inhibit demyelination directly by targeting an enzyme called peptidyl arginine deiminase 2.
Nearly three million people around the world wake up every day managing a disease that has no cure, and the number keeps climbing. That reality is what makes new approaches to multiple sclerosis worth paying attention to, and it is the space where Quantum BioPharma (NASDAQ: QNTM) is working to make a difference with its lead drug candidate: Lucid-MS.
Multiple sclerosis is a chronic disease of the central nervous system in which the immune system attacks myelin, the protective coating around nerve fibers in the brain and spinal cord. Global prevalence rose from about 2.3 million people in 2013 to roughly 2.8 million in 2020 and had climbed to an estimated 2.9 million by 2023.
In the United States alone, close to one million people are living with the disease. A landmark study published in the journal “Neurology” found the figure was more than double what had previously been assumed for decades. The disease typically strikes people in their 20s and 30s, with women being diagnosed at roughly twice the rate of men.
The symptoms of MS can be unpredictable and wide ranging. They include fatigue, vision problems, numbness, balance and coordination trouble, and cognitive changes, all stemming from damaged communication between the brain and the rest of the body. Because the disease can progress differently in every patient, diagnosis and treatment planning remain genuinely difficult for physicians.
Most currently available therapies fall into a category called disease-modifying therapies, and the majority of these treatments work by suppressing or modulating the immune system. Interferons, glatiramer acetate and newer monoclonal antibodies are among the most widely prescribed options, and research shows these drugs can meaningfully reduce relapse rates for people with relapsing forms of the disease.
But that same body of research points to real limitations. Injectable immunomodulatory therapies suffer from poor long-term adherence, with roughly half of patients discontinuing treatment within the first year, according to the same published review. Treatments for progressive forms of MS remain especially elusive, and recent research notes that no currently approved therapy directly reverses the neurodegeneration that drives long-term disability.
That gap between managing relapses and actually protecting nerve tissue is where newer approaches are working to make progress. Researchers are increasingly interested in neuroprotective and remyelinating strategies, ones that aim to preserve or restore the myelin sheath itself rather than only calming the immune system’s attack on it.
Quantum BioPharma’s Lucid-MS candidate fits into that emerging category. Rather than suppressing immune activity, the compound is designed to inhibit demyelination directly by targeting an enzyme called peptidyl arginine deiminase 2, which when overactive has been linked to myelin breakdown. Quantum reports that in preclinical animal studies, the compound prevented myelin degradation, and findings from that research have appeared in peer-reviewed outlets, including the Journal of Medicinal Chemistry and Proceedings of the National Academy Sciences.
The company recently reached a significant milestone in its efforts. The FDA cleared Quantum BioPharma’s Investigational New Drug (“IND”) application for Lucid-MS, allowing the company to move the candidate into phase 2 clinical trials. That stage of testing is designed to evaluate whether the drug is effective in treating MS in a controlled patient population and also allows for continued safety monitoring.
The global market for MS therapeutics reflects just how much is riding on finding better options. Precedence Research estimates that market at approximately $34.8 billion in 2025, with projections suggesting it could nearly double by 2035 as new mechanisms of action reach patients.
For the millions of people currently living with multiple sclerosis, and the hundreds of thousands more diagnosed each year, incremental progress in the lab eventually has to translate into new choices at the pharmacy. Quantum BioPharma is one of several companies working toward that goal, betting that protecting nerve tissue directly, rather than only quieting the immune system, could open a new chapter in how the disease is treated.
For more information, visit www.QuantumBioPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- In the United States alone, close to one million people are living with MS, with a landmark study finding that figure was more than double what had previously been assumed.
- Treatments for progressive forms of MS remain especially elusive, and recent research notes that no currently approved therapy directly reverses the neurodegeneration that drives long-term disability.
- Quantum BioPharma’s Lucid-MS candidate is designed to inhibit demyelination directly by targeting an enzyme called peptidyl arginine deiminase 2.
Nearly three million people around the world wake up every day managing a disease that has no cure, and the number keeps climbing. That reality is what makes new approaches to multiple sclerosis worth paying attention to, and it is the space where Quantum BioPharma (NASDAQ: QNTM) is working to make a difference with its lead drug candidate: Lucid-MS.
Multiple sclerosis is a chronic disease of the central nervous system in which the immune system attacks myelin, the protective coating around nerve fibers in the brain and spinal cord. Global prevalence rose from about 2.3 million people in 2013 to roughly 2.8 million in 2020 and had climbed to an estimated 2.9 million by 2023.
In the United States alone, close to one million people are living with the disease. A landmark study published in the journal “Neurology” found the figure was more than double what had previously been assumed for decades. The disease typically strikes people in their 20s and 30s, with women being diagnosed at roughly twice the rate of men.
The symptoms of MS can be unpredictable and wide ranging. They include fatigue, vision problems, numbness, balance and coordination trouble, and cognitive changes, all stemming from damaged communication between the brain and the rest of the body. Because the disease can progress differently in every patient, diagnosis and treatment planning remain genuinely difficult for physicians.
Most currently available therapies fall into a category called disease-modifying therapies, and the majority of these treatments work by suppressing or modulating the immune system. Interferons, glatiramer acetate and newer monoclonal antibodies are among the most widely prescribed options, and research shows these drugs can meaningfully reduce relapse rates for people with relapsing forms of the disease.
But that same body of research points to real limitations. Injectable immunomodulatory therapies suffer from poor long-term adherence, with roughly half of patients discontinuing treatment within the first year, according to the same published review. Treatments for progressive forms of MS remain especially elusive, and recent research notes that no currently approved therapy directly reverses the neurodegeneration that drives long-term disability.
That gap between managing relapses and actually protecting nerve tissue is where newer approaches are working to make progress. Researchers are increasingly interested in neuroprotective and remyelinating strategies, ones that aim to preserve or restore the myelin sheath itself rather than only calming the immune system’s attack on it.
Quantum BioPharma’s Lucid-MS candidate fits into that emerging category. Rather than suppressing immune activity, the compound is designed to inhibit demyelination directly by targeting an enzyme called peptidyl arginine deiminase 2, which when overactive has been linked to myelin breakdown. Quantum reports that in preclinical animal studies, the compound prevented myelin degradation, and findings from that research have appeared in peer-reviewed outlets, including the Journal of Medicinal Chemistry and Proceedings of the National Academy Sciences.
The company recently reached a significant milestone in its efforts. The FDA cleared Quantum BioPharma’s Investigational New Drug (“IND”) application for Lucid-MS, allowing the company to move the candidate into phase 2 clinical trials. That stage of testing is designed to evaluate whether the drug is effective in treating MS in a controlled patient population and also allows for continued safety monitoring.
The global market for MS therapeutics reflects just how much is riding on finding better options. Precedence Research estimates that market at approximately $34.8 billion in 2025, with projections suggesting it could nearly double by 2035 as new mechanisms of action reach patients.
For the millions of people currently living with multiple sclerosis, and the hundreds of thousands more diagnosed each year, incremental progress in the lab eventually has to translate into new choices at the pharmacy. Quantum BioPharma is one of several companies working toward that goal, betting that protecting nerve tissue directly, rather than only quieting the immune system, could open a new chapter in how the disease is treated.
For more information, visit www.QuantumBioPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
